Mayer, Jutta S. https://orcid.org/0000-0002-5328-5893
Hees, Katharina
Medda, Juliane
Grimm, Oliver
Asherson, Philip
Bellina, Mariano
Colla, Michael
Ibáñez, Pol
Koch, Elena
Martinez-Nicolas, Antonio
Muntaner-Mas, Adrià
Rommel, Anna
Rommelse, Nanda
de Ruiter, Saskia
Ebner-Priemer, Ulrich W.
Kieser, Meinhard
Ortega, Francisco B.
Thome, Johannes
Buitelaar, Jan K.
Kuntsi, Jonna
Ramos-Quiroga, J. Antoni
Reif, Andreas
Freitag, Christine M.
Funding for this research was provided by:
Horizon 2020 Framework Programme (667302)
Article History
Received: 23 October 2017
Accepted: 18 December 2017
First Online: 26 February 2018
Authors’ information
: Not applicable.
: The study protocol was first ethically reviewed and approved by the institutional review board of the Medical Faculty, Goethe University, Frankfurt am Main, German (No. 353/16, 13 January 2017). Subsequent approval of this vote was done by the ethical committee of Vall d’Hebron Research Institute, Barcelona, Spain (No. PR(AG)105/2017, 19 April 2017), King’s College London, UK (No. 17/LO/0958, 11 July 2017), and Radboud University Medical Centre, Nijmegen, The Netherlands (No. 2017-3238, 05 October 2017). The Informed Consent Form will be provided by the investigator before the participants’ inclusion in the study.
: Not applicable.
: AR has received grant support and speaker’s honoraria from Medice and Servier.CMF receives royalties for books on ADHD and ASD. She has served as consultant for Desitin and Roche with regard to ASD.JARQ was on the speakers’ bureau and/or acted as consultant for Eli-Lilly, Janssen-Cilag, Novartis, Shire, Lundbeck, Almirall, B-Gaze, and Rubió in the last three years. He also received travel awards (air tickets and hotel) for taking part in psychiatric meetings from Janssen-Cilag, Rubió, Shire, and Eli- Lilly. The ADHD Program chaired by him received unrestricted educational and research support from the following pharmaceutical companies in the last three years: Eli-Lilly, Lundbeck, Janssen- Cilag, Actelion, Shire, and Rubió.JKB has been in the past three years a consultant to / member of advisory board of / and/or speaker for Janssen Cilag BV, Eli Lilly, Lundbeck, Shire, Roche, Medice, Novartis, and Servier. He has received research support from Roche and Vifor. He is not an employee of any of these companies and is not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties.MB received travel awards (air tickets and hotel) for taking part in psychiatric meetings from Janssen-Cilag and Shire in the last three years.PA has received funding for research by Vifor Pharma and has given sponsored talks and been an advisor for Shire, Janssen–Cilag, Eli-Lilly, Flynn Pharma, and Pfizer, regarding the diagnosis and treatment of ADHD. All funds are received by King’s College London and used for studies of ADHD.The remaining authors do not report any conflicts of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.